Please provide your email address to receive an email when new articles are posted on . A novel SK ion channel inhibitor more often converted atrial fibrillation to sinus rhythm compared with placebo.
This new article publication from Acta Pharmaceutica Sinica B, discusses how structure-guided design of picomolar-level macrocyclic TRPC5 channel inhibitors with antidepressant activity. Recent ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions ...
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results